Filing Analysis
Rafael Holdings, Inc. filed an 8-K to announce the distribution of its earnings release for the fiscal quarter ended April 30, 2026. The filing serves as a formal notice that financial results have been posted to the company's website and distributed via wire service.
📋 Key Facts
- The filing date is June 11, 2026.
- The report covers the fiscal quarter ended April 30, 2026.
- The earnings release is attached as Exhibit 99.1.
- The company's Class B common stock is traded on the New York Stock Exchange under the symbol RFL.
Rafael Holdings announced that the final patient has completed the 96-week study visit in the pivotal Phase 3 TransportNPC study for Trappsol Cyclo. The company expects to release topline data from the main study cohort in the second half of 2026.
📋 Key Facts
- Completion of the final 96-week study visit for the last patient in the Phase 3 TransportNPC study.
- The study evaluates Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C.
- Topline data for the main study cohort is anticipated in H2 2026.
Rafael Holdings announced that its subsidiary, Cyclo Therapeutics, LLC, has entered into an exclusive licensing agreement with the Massachusetts Institute of Technology (MIT). The agreement covers a patent for the use of cyclodextrins to treat Alzheimer's Disease patients carrying the ApoE4 genetic mutation.
📋 Key Facts
- Exclusive licensing agreement with MIT for U.S. Patent No. 12285440.
- The patent focuses on Alzheimer's Disease (AD) patients with the ApoE4 genetic mutation.
- The agreement was announced on April 22, 2026.
- The technology involves the use of cyclodextrins.
Rafael Holdings, Inc. announced its financial results for the fiscal quarter ended January 31, 2026. The company furnished the earnings release via Item 2.02 and included the full press release as an exhibit.
📋 Key Facts
- The filing reports results for the fiscal quarter ended January 31, 2026.
- The report was filed on March 16, 2026.
- The earnings release was furnished as Exhibit 99.1.
- The information is furnished under Item 2.02 (Results of Operations and Financial Condition) and is not deemed 'filed' for liability purposes.